Transformation by oncogenic Ras expands the early genomic response to transforming growth factor β in intestinal epithelial cells

Neoplasia

Volumn 10, Issue 10, 2008, Pages 1073-1082

  Allen, Carl E ^a   Du, Jianguo ^a   Jiang, Bo ^a   Huang, Qin ^a   Yakovich, Adam J ^a   Barnard, John A ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; FRAGILE X MENTAL RETARDATION GENE 2; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC TRANSCRIPTION; GENOME ANALYSIS; INTESTINE EPITHELIUM CELL; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PRIORITY JOURNAL; RAT; TUMOR PROMOTION; UNINDEXED SEQUENCE; UPREGULATION;

EID: 54249143942     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07739     Document Type: Article

References (64)

1. Akhurst RJ and Derynck R (2001). TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol 11, S44-S51.
2. Derynck R, Akhurst RJ, and Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29, 117-129.
3. Massague J, Blain SW, and Lo RS (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103, 295-309.
4. Roberts AB and Wakefield LM (2003). The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 100, 8621-8623.
5. Bierie B and Moses HL (2006). TGF-beta and cancer. Cytokine Growth Factor Rev 17, 29-40.
6. Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, and Arteaga CL (2003). Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol 23, 8691-8703.
7. Deane NG, Lee H, Hamaamen J, Ruley A, Washington MK, LaFleur B, Thorgeirsson SS, Price R, and Beauchamp RD (2004). Enhanced tumor formation in cyclin D1 x transforming growth factor beta1 double transgenic mice with characterization by magnetic resonance imaging. Cancer Res 64, 1315-1322.
8. Derynck R and Zhang YE (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577-584.
9. Massague J and Wotton D (2000). Transcriptional control by the TGF-beta/ Smad signaling system. EMBO J 19, 1745-1754.
10. Massague J and Gomis RR (2006). The logic of TGF-beta signaling. FEBS Lett 580, 2811-2820.
11. Wu T, Rezai B, Rashid A, Michael CL, Cayouette MC, Kim C, and Sani N (1997). Genetic alterations and epithelial dysplasia in juvenile polyposis syndrome and sporadic juvenile polyps. Am J Pathol 150, 939-947.
12. Massague J, Seoane J, and Wotton D (2005). Smad transcription factors. Genes Dev 19, 2783-2810.
13. Yue J and Mulder KM (2001). Transforming growth factor-beta signal transduction in epithelial cells. Pharmacol Ther 91, 1-34.
14. Crespo P and Leon J (2000). Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci 57, 1613-1636.
15. Macaluso M, Russo G, Cinti C, Bazan V, Gebbia N, and Russo A (2002). Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol 192, 125-130.
16. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, and Vogelstein B (1987). Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293-297.
17. Mulder KM (2000). Role of Ras and MAPKs in TGFbeta signaling. Cytokine Growth Factor Rev 11, 23-35.
18. Bulus NM, Sheng HM, Sizemore N, Oldham SM, Barnett JV, Coffey RJ, Beauchamp DR, and Barnard JA (2000). Ras-mediated suppression of TGFbetaRII expression in intestinal epithelial cells involves Raf-independent signaling. Neoplasia 2, 357-364.
19. Jiang B, Zhang JS, Du J, Urrutia R, and Barnard J (2003). Growth inhibitory signalling by TGFbeta is blocked in Ras-transformed intestinal epithelial cells at a post-receptor locus. Cell Signal 15, 699-708.
20. Saha D, Datta PK, and Beauchamp RD (2001). Oncogenic ras represses transforming growth factor-beta/Smad signaling by degrading tumor suppressor Smad4. J Biol Chem 276, 29531-29537.
21. Winesett MP, Ramsey GW, and Barnard JA (1996). Type II TGF(beta) receptor expression in intestinal cell lines and in the intestinal tract. Carcinogenesis 17, 989-995.
22. Du J, Jiang B, Coffey RJ, and Barnard J (2004). Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta. Mol Cancer Res 2, 233-241.
23. Yoo J, Ghiassi M, Jirmanova L, Balliet AG, Hoffman B, Fornace AJ Jr, Liebermann DA, Bottinger EP, and Roberts AB (2003). Transforming growth factor-beta-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation. J Biol Chem 278, 43001-43007.
24. Benckert C, Jonas S, Cramer T, Von Marschall Z, Schafer G, Peters M, Wagner K, Radke C, Wiedenmann B, Neuhaus P, et al. (2003). Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63, 1083-1092.
25. Ohtsuki M and Massague J (1992). Evidence for the involvement of protein kinase activity in transforming growth factor-beta signal transduction. Mol Cell Biol 12, 261-265.
26. Shen M, Yoshida E, Yan W, Kawamoto T, Suardita K, Koyano Y, Fujimoto K, Noshiro M, and Kato Y (2002). Basic helix-loop-helix protein DEC1 promotes chondrocyte differentiation at the early and terminal stages. J Biol Chem 277, 50112-50120.
27. Nagarajan RP, Zhang J, Li W, and Chen Y (1999). Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J Biol Chem 274, 33412-33418.
28. Breier G, Blum S, Peli J, Groot M, Wild C, Risau W, and Reichmann E (2002). Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. Int J Cancer 97, 142-148.
29. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, and Arteaga CL (2000). Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 275, 36803-36810.
30. Yang F, Tuxhorn JA, Ressler SJ, McAlhany SJ, Dang TD, and Rowley DR (2005). Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res 65, 8887-8895.
31. Chien W, Yin D, Gui D, Mori A, Frank JM, Said J, Kusuanco D, Marchevsky A, McKenna R, and Koeffler HP (2006). Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells. Mol Cancer Res 4, 591-598.
32. Levy L and Hill CS (2005). Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 25, 8108-8125.
33. Chen CR, Kang Y, and Massague J (2001). Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA 98, 992-999.
34. Hocevar BA, Brown TL, and Howe PH (1999). TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 18, 1345-1356.
35. Oft M, Heider KH, and Beug H (1998). TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 8, 1243-1252.
36. Larsson J, Goumans MJ, Sjostrand LJ, van Rooijen MA, Ward D, Leveen P, Xu X, ten Dijke P, Mummery CL, and Karlsson S (2001). Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO J 20, 1663-1673.
37. Tsushima H, Ito N, Tamura S, Matsuda Y, Inada M, Yabuuchi I, Imai Y, Nagashima R, Misawa H, Takeda H, et al. (2001). Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 7, 1258-1262.
38. Picon A, Gold LI, Wang J, Cohen A, and Friedman E (1998). A subset of human colon cancers expresses elevated levels of transforming growth factor beta 1. Cancer Epidemiol Biomarkers Prev 7, 497-504.
39. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, and Cohen A (1995). High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 4, 549-554.
40. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB III, and Hamilton SR (2001). Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344, 1196-1206.
41. Siegel PM, Shu W, Cardiff RD, Muller WJ, and Massague J (2003). Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 100, 8430-8435.
42. Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, Mansour SJ, Ahn NG, and Kerbel RS (2000). Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 60, 490-498.
43. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, and Gress TM (2001). TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 93, 204-211.
44. Fujimoto K, Sheng H, Shao J, and Beauchamp RD (2001). Transforming growth factor-beta1 promotes invasiveness after cellular transformation with activated Ras in intestinal epithelial cells. Exp Cell Res 266, 239-249.
45. Geiser AG, Kim SJ, Roberts AB, and Sporn MB (1991). Characterization of the mouse transforming growth factor-beta 1 promoter and activation by the Ha-Ras oncogene. Mol Cell Biol 11, 84-92.
46. Filmus J, Zhao J, and Buick RN (1992). Overexpression of H-ras oncogene induces resistance to the growth-inhibitory action of transforming growth factor beta-1 (TGF-beta 1) and alters the number and type of TGF-beta 1 receptors in rat intestinal epithelial cell clones. Oncogene 7, 521-526.
47. Kretzschmar M, Doody J, Timokhina I, and Massague J (1999). A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 13, 804-816.
48. Jazag A, Ijichi H, Kanai F, Imamura T, Guleng B, Ohta M, Imamura J, Tanaka Y, Tateishi K, Ikenoue T, et al. (2005). Smad4 silencing in pancreatic cancer cell lines using stable RNA interference and gene expression profiles induced by transforming growth factor-beta. Oncogene 24, 662-671.
49. Kretschmer A, Moepert K, Dames S, Sternberger M, Kaufmann J, and Klippel A (2003). Differential regulation of TGF-beta signaling through Smad2, Smad3 and Smad4. Oncogene 22, 6748-6763.
50. Grunert S, Jechlinger M, and Beug H (2003). Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4, 657-665.
51. Qian J, Niu J, Li M, Chiao P, and Tsao MS (2005). In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res 65, 5045-5053.
52. Duffy MJ (2004). The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10, 39-49.
53. Bergers G and Benjamin LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3, 401-410.
54. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536.
55. Ahmed Y, Nouri A, and Wieschaus E (2002). Drosophila Apc1 and Apc2 regulate Wingless transduction throughout development. Development 129, 1751-1762.
56. Grady WM and Markowitz SD (2002). Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 3, 101-128.
57. Bonner AE, Lemon WJ, Devereux TR, Lubet RA, and You M (2004). Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas. Oncogene 23, 1166-1176.
58. Gu Y and Nelson DL (2003). FMR2 function: insight from a mouse knockout model. Cytogenet Genome Res 100, 129-139.
59. Ma C and Staudt LM (1996). LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias. Blood 87, 734-745.
60. Hiwatari M, Taki T, Taketani T, Taniwaki M, Sugita K, Okuya M, Eguchi M, Ida K, and Hayashi Y (2003). Fusion of an AF4-related gene, LAF4, to MLL in childhood acute lymphoblastic leukemia with t(2;11)(q11;q23). Oncogene 22, 2851-2855.
61. Imamura T, Morimoto A, Ikushima S, Kakazu N, Hada S, Tabata Y, Yagi T, Inaba T, Hibi S, Sugimoto T, et al. (2002). A novel infant acute lymphoblastic leukemia cell line with MLL-AF5q31 fusion transcript. Leukemia 16, 2302-2308.
62. von Bergh AR, Beverloo HB, Rombout P, van Wering ER, van Weel MH, Beverstock GC, Kluin PM, Slater RM, and Schuuring E (2002). LAF4, an AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia. Genes Chromosomes Cancer 35, 92-96.
63. Su MA, Wisotzkey RG, and Newfeld SJ (2001). A screen for modifiers of decapentaplegic mutant phenotypes identifies lilliputian, the only member of the fragile-X/ Burkitt's lymphoma family of transcription factors in Drosophila melanogaster. Genetics 157, 717-725.
64. Wittwer F, van der Straten A, Keleman K, Dickson B, and Hafen E (2001). Lilliputian: an AF4/FMR2-related protein that controls cell identity and cell growth. Development 128, 791-800.